Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade
Just days after biotech rivals formed an IP alliance around CRISPR/Cas9 gene editing tech, Editas Medicines $EDIT has fired back in their patent war by bagging an exclusive license to what is being billed as an upgrade to improve researchers’ ability to edit genes and fight disease.
Like its foundation IP, this new tech, which substitutes a new DNA editing “tool” called Cpf1 in place of Cas9, comes from Feng Zhang at MIT. Cambridge, MA-based Editas gained their new Cpf1 tech — along with new IP on Cas9 — from the Broad Institute of MIT and Harvard, Harvard University, MIT, Wageningen University, the University of Iowa, and the University of Tokyo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
